Wird geladen...

Predicting prostate cancer many years before diagnosis: how and why?

Evidence of reduced prostate cancer mortality from randomized trials in Europe supports early detection of prostate cancer with prostate-specific antigen (PSA). Yet PSA screening has generated considerable controversy: it is far from clear that the benefits outweigh risks, in terms of overdiagnosis...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Vickers, Andrew J., Lilja, Hans
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2011
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3373007/
https://ncbi.nlm.nih.gov/pubmed/22101902
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00345-011-0795-8
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!